Spreadsheet: 2de92e95-ad38-4cdb-b62c-dd599158b2e1
Sheet: Tb45

 | Estimated Vaccination Coverage^ with Individual Vaccines and Vaccination Series Among Children 19-35 Months of Age by Race/Ethnicity* -- US, National Immunization Surve Q1/2012-Q4/2012†
[NAME] | US National | White only,                        non-Hispanic | Black only,                         non-Hispanic | Hispanic | American Indian or [NAME] only, non-Hispanic | Asian only, non-Hispanic | Native Hawaiian or other Pacific Islander only, non-Hispanic | Multiple Race, non-Hispanic
3+DTaP¥ | 94.3±0.7 | 94.8±0.8 | 94.0±1.6 | 93.5±1.9 | 95.6±3.3 | 96.1±2.1 | NA | 95.1±2.0
4+DTaP‡ | 82.5±1.2 | 83.6±1.5 | 79.6±3.1 | 80.8±2.9 | 88.2±5.9 | 88.1±4.3 | NA | 85.6±3.6
3+Polio§ | 92.8±0.7 | 93.0±0.9 | 92.9±1.8 | 92.5±1.8 | 95.2±3.4 | 92.3±3.6 | NA | 93.3±2.3
1+MMRll | 90.8±0.8 | 90.9±1.0 | 90.9±2.1 | 90.7±2.0 | 92.0±5.0 | 89.8±5.2 | NA | 92.3±2.6
Hib-PS¶ | 93.3±0.7 | 93.7±0.9 | 91.1±2.2 | 93.5±1.7 | 94.5±3.9 | 94.9±2.2 | NA | 94.0±2.2
Hib-FS** | 80.9±1.2 | 82.2±1.4 | 77.5±3.3 | 79.5±2.8 | 84.7±7.1 | 86.1±4.4 | NA | 82.5±3.9
3+HepB†† | 89.7±0.9 | 89.3±1.1 | 89.7±2.2 | 89.4±2.1 | 94.0±3.9 | 93.2±2.7 | NA | 92.2±2.6
[NAME] | 71.6±1.4 | 69.2±1.6 | 74.9±3.6 | 73.9±3.4 | NA | 71.6±6.6 | NA | 75.9±4.8
1+Var§§ | 90.2±0.8 | 89.8±1.0 | 90.4±2.1 | 90.9±2.1 | 92.5±4.5 | 91.9±3.2 | NA | 90.9±2.9
3+PCV | 92.3±0.8 | 92.7±1.0 | 91.2±2.0 | 92.4±1.8 | 94.0±4.0 | 90.7±3.3 | NA | 94.0±2.2
4+PCV¶¶ | 81.9±1.1 | 83.5±1.4 | 77.1±3.5 | 82.1±2.5 | NA | 80.7±5.1 | NA | 84.1±3.7
1+ HepA*** | 81.5±1.1 | 79.4±1.4 | 83.1±2.9 | 84.2±2.5 | NA | 87.2±3.9 | NA | 80.2±4.9
2+HepA††† | 53.0±1.5 | 52.6±1.8 | 52.0±3.9 | 54.4±3.4 | NA | 57.5±7.7 | NA | 49.4±5.7
Rotavirus‡‡‡ | 68.6±1.4 | 70.5±1.6 | 60.4±4.0 | 70.0±3.1 | NA | 69.9±7.1 | NA | 69.3±5.4
4:3:1§§§ | 80.5±1.2 | 81.3±1.5 | 77.9±3.2 | 79.5±3.0 | 87.6±6.0 | 83.2±5.9 | NA | 83.0±4.0
(4:3:1:3*) | 76.0±1.3 | 76.8±1.7 | 72.5±3.5 | 75.4±3.0 | 81.6±7.9 | 79.9±6.1 | NA | 77.7±4.4
4:3:1:3*:3:1¶¶¶¶ | 71.9±1.4 | 72.4±1.7 | 68.4±3.6 | 71.4±3.2 | 79.1±8.5 | 77.7±6.2 | NA | 74.6±4.6
4:3:1:3*:3:1:4**** | 68.4±1.4 | 69.3±1.7 | 64.8±3.8 | 67.8±3.2 | NA | 71.6±6.6 | NA | 71.5±4.8
 | ^ Estimate=NA (Not Available) if the unweighted sample size for the denominator was <30 or (CI half width)/Estimate > 0.588 or (CI half width) >10. Estimates presented as point estimate (%) ± 95% Confidence Interval.
 | * Self-reported by respondent. Children of Hispanic ethnicity may be of any race.
 | † Children in the Q1/2012-Q4/2012 National Immunization Survey were born from January 2009 through May 2011.
 | ¥ 3 or more doses of any diphtheria and tetanus toxoids and pertussis vaccines including diphtheria and tetanus toxoids, and any acellular pertussis vaccine (DTaP/DTP/DT).
 | ‡ 4 or more doses of DTaP.
 | § 3 or more doses of any poliovirus vaccine.
 | ll 1 or more doses of measles-mumps-rubella vaccine.
 | ¶ Primary series Hib:  ≥2 or ≥3 doses of Hib vaccine depending on product type received.
 | ** Full series Hib:  ≥3 or ≥4 doses of Hib vaccine depending on product type received (includes primary series plus the booster dose).
 | †† 3 or more doses of hepatitis B vaccine.
 | ‡‡ 1 or more doses of hepatitis B vaccine administered from birth through age 3 days.
 | §§ 1 or more doses of varicella at or after child's first birthday, unadjusted for history of varicella illness.
 | |||| 3 or more doses of pneumococcal conjugate vaccine (PCV).
 | ¶¶ 4 or more doses of PCV.
 | *** 1 or more doses of Hepatitis A vaccine.
 | ††† 2 or more doses of Hepatitis A vaccine.
 | ‡‡‡ ≥2 or ≥3 doses of [NAME] vaccine, depending on product type received (≥2 doses for Rotarix® [RVI] or ≥3 doses for RotaTeq® [RV5]).
 | §§§ 4 or more doses of DTaP, 3 or more doses of poliovirus vaccine, and 1 or more doses of any MMR vaccine.
 | |||||| 4:3:1 plus the full series Hib.
 | ¶¶¶¶ 4:3:1 plus full series of Hib vaccine, 3 or more doses of HepB vaccine, and 1 or more doses of varicella vaccine.
 | **** 4:3:1 plus full series Hib vaccine, 3 or more doses of HepB, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.